These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 31837884)

  • 21. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
    de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
    Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.
    Troiano G; Caponio VCA; Zhurakivska K; Arena C; Pannone G; Mascitti M; Santarelli A; Lo Muzio L
    Cell Prolif; 2019 Mar; 52(2):e12537. PubMed ID: 30443950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
    Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
    J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation and characterisation of prognostically significant PD-L1
    Young RJ; Bressel M; Porceddu S; Cernelc J; Savas P; Liu H; Urban D; Thai AA; Cooper C; Fua T; Neeson P; Rischin D; Solomon B
    Oral Oncol; 2020 Feb; 101():104516. PubMed ID: 31838340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
    Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
    Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of PD-L1 expression in squamous cell cancer of unknown primary and oropharyngeal squamous cell carcinoma.
    Schmidl B; Voßenkämper KA; Stark L; Boxberg M; Stögbauer F; Feigl K; Winter C; Pickhard A; Wollenberg B; Wirth M
    Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1991-1997. PubMed ID: 36576530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
    Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
    Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of choice of materials and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell carcinoma.
    De Meulenaere A; Vermassen T; Creytens D; Aspeslagh S; Deron P; Duprez F; Rottey S; Van Dorpe JA; Ferdinande L
    Histopathology; 2018 Sep; 73(3):500-509. PubMed ID: 29768723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer.
    Badr M; Jöhrens K; Allgäuer M; Boxberg M; Weichert W; Tinhofer I; Denkert C; Schirmacher P; Stenzinger A; Budczies J
    Cancer Immunol Immunother; 2019 Sep; 68(9):1443-1454. PubMed ID: 31444607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer.
    Hong AM; Ferguson P; Dodds T; Jones D; Li M; Yang J; Scolyer RA
    Oral Oncol; 2019 May; 92():33-39. PubMed ID: 31010620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma.
    Tsakiroglou AM; Fergie M; Oguejiofor K; Linton K; Thomson D; Stern PL; Astley S; Byers R; West CML
    Br J Cancer; 2020 Feb; 122(4):539-544. PubMed ID: 31806878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.
    Li XS; Li JW; Li H; Jiang T
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
    Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
    Front Immunol; 2018; 9():2077. PubMed ID: 30254644
    [No Abstract]   [Full Text] [Related]  

  • 35. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.
    Patel JJ; Levy DA; Nguyen SA; Knochelmann HM; Day TA
    Head Neck; 2020 Apr; 42(4):774-786. PubMed ID: 31762164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
    Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma.
    Steuer CE; Griffith CC; Nannapaneni S; Patel MR; Liu Y; Magliocca KR; El-Deiry MW; Cohen C; Owonikoko TK; Shin DM; Chen ZG; Saba NF
    Mol Cancer Ther; 2018 Mar; 17(3):710-716. PubMed ID: 29440293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
    Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A
    J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinicopathological and prognostic significance of PD-L1 expression in oral squamous cell carcinoma: a meta analysis].
    Zou B; Xu K; Liu XB; Fan QC; Yuan DY
    Shanghai Kou Qiang Yi Xue; 2018 Feb; 27(1):100-105. PubMed ID: 29946653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.